Pfizer Tuesday said it expects global sales of its coronavirus vaccine to reach $26 billion in 2021, a milestone that would make it the biggest selling pharmaceutical product in the world and helps illustrate why Pfizer is planning to expand use of mRNA technology for other vaccines and therapies.

Sales of its mRNA vaccine are likely to eclipse Humira, the rheumatoid arthritis drug manufactured by AbbVie with annual revenue around $20 billion, currently the world’s top seller. Pfizer had $3.5 billion on coronavirus vaccine sales in the first quarter.

Pfizer, which is in partnership with Germany’s BioNTech for vaccine development and sales, has said it expects to manufacture 2.5 billion doses of the two-shot vaccine in 2021. It has agreements to sell 300 million to the United States by late summer.

The company is working on creating seasonal flu shots using the same mRNA lipid nanoparticle technology, which has vaulted from lab benches and a single drug for rare disease a year ago into the most effective vaccine that is in demand around the world.

Advertise with us

“Pfizer has emerged as a leader in mRNA development, and we are exploring a wide range of opportunities for the technology,‘‘ CEO Albert Bourla said Tuesday in a conference call for investors. Without disclosing specifics, Mr. Bourla said the company is working on other vaccines for infectious-disease as well as creating a research pipeline for therapeutics for cancer and genetic disease.

Pfizer and it’s rival in the mRNA coronavirus vaccine business, Moderna, have both said they intend to make a profit on vaccine sales during the pandemic. Both of the vaccines have proven that mRNA can be used to develop and manufacture a vaccine in as little as six months.

More traditional vaccines manufactured by AstraZeneca and Johnson & Johnson have suffered from delays and manufacturing stumbles, including a cross-contamination episode at a Baltimore plant of biodefense contractor Emergent BioSolutions. AstraZeneca and Johnson & Johnson have said they do not intend to profit from their vaccines during the pandemic.

This story was originally published with images that are no longer available.